Cancer

hC Bioscience's Preclinical Study Shows Promise for tRNA-Based Cancer Therapy

Retrieved on: 
Wednesday, June 7, 2023
Cancer, PTC Therapeutics, Therapy, Mutation, Patient, Small RNA, Medical imaging, Telescopic sight

Boston, Massachusetts--(Newsfile Corp. - June 7, 2023) - hC Bioscience announced its tRNA-based therapy demonstrated proof-of-concept in an in vivo model of metastatic colorectal cancer with 75% tumor growth inhibition.

Key Points: 
  • Boston, Massachusetts--(Newsfile Corp. - June 7, 2023) - hC Bioscience announced its tRNA-based therapy demonstrated proof-of-concept in an in vivo model of metastatic colorectal cancer with 75% tumor growth inhibition.
  • Because nonsense mutations drive an estimated 10-15% of cancers, tRNA-based therapy represents a potential new modality for the treatment of cancer.
  • hC Bioscience's engineered tRNA demonstrated preclinical proof-of-concept in metastatic colorectal cancer, paving the way for treating cancer with tRNA-based therapy.
  • A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

EQS-News: Defence Therapeutics Inc.: DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCER

Retrieved on: 
Saturday, June 10, 2023
Transfer, Survival rate, Pancreatic cancer, ARM, Cancer, Microsoft Exchange Server, Animal, Ralph Bates Pancreatic Cancer Research Fund, Melanoma, China International Technology Transfer Center, Neoplasm, Mortality, Research, Therapy, Disease, A1, Vaccine, Defense

Based on these impressive data, Defence contracted Transbiotech Biotechnology Research and Transfer Center, to test the potency of its ARM vaccine in animals with pre-established pancreatic tumors.

Key Points: 
  • Based on these impressive data, Defence contracted Transbiotech Biotechnology Research and Transfer Center, to test the potency of its ARM vaccine in animals with pre-established pancreatic tumors.
  • Therefore, developing a cancer vaccine capable of eradicating this disease will be a major leap in the global fight against cancer.
  • A successful treatment of pancreatic cancer with the ARM vaccine would certainly widen the application of this therapy to other “hard to treat” cancers," says Mr. Plouffe, CEO and president of Defence.
  • According to Hirshberg Foundation for Pancreatic Cancer Research, pancreatic cancer has the highest mortality rate of all major cancers.

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

Retrieved on: 
Friday, June 9, 2023
CD19, ICML, Lymphoma, Cancer, B-cell lymphoma, Immunotherapy, ASCO, CAR, International Conference on Computer and Information Technology, American Society of Clinical Oncology, Kite Pharma, Patient, Annual general meeting, Pivotal, Therapy, Society, Conference, Safety, Chair, Vaccine

This presentation will feature additional data on the 33 CAR T naïve patients treated with the Alloy™ manufacturing process across different CAR T dosing and lymphodepletion regimens.

Key Points: 
  • This presentation will feature additional data on the 33 CAR T naïve patients treated with the Alloy™ manufacturing process across different CAR T dosing and lymphodepletion regimens.
  • The ALPHA/ALPHA2 Phase 1 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19.
  • Allogene is currently enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in LBCL and expects to complete enrollment in 1H2024.
  • Allogene Presentation at the 2023 ICML Lugano:
    Presenter: Dr. Frederick Locke, M.D., Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy; program co-leader, Immuno-Oncology, Moffitt Cancer Center Tampa, Florida

Lifshitz Law PLLC Announces Investigations of Iris Energy Limited (NASDAQ: IREN), F45 Training Holdings, Inc. (NYSE: FXLV), Generac Holdings Inc. (NYSE: GNRC), and NeoGenomics, Inc. (NASDAQ: NEO)

Retrieved on: 
Friday, June 9, 2023
IPO, NeoGenomics, Generac, Telephone, Marie Cassidy, Cancer, Advertising, Hewlett, Safety, Mail

If you are an Iris investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an Iris investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • If you are a F45 investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

National Work & Cancer Conference Brings Attention To Disability And Employment For American Workers, Allsup Explains

Retrieved on: 
Friday, June 9, 2023
Survivor, Social Security Disability Insurance, Employment, Disability, Ontario Disability Employment Network, SSDI, Social Security Administration, Patient, Social Security, AES, Social, Social work, Conference, Disease, Health insurance, Insurance, Cancer, Career

Belleville, Illinois, June 09, 2023 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work, veterans disability appeals, and healthcare insurance services, is excited to sponsor Cancer and Careers’ 13th Annual National Conference on Work & Cancer , scheduled for Friday, June 23, 2023.

Key Points: 
  • Belleville, Illinois, June 09, 2023 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work, veterans disability appeals, and healthcare insurance services, is excited to sponsor Cancer and Careers’ 13th Annual National Conference on Work & Cancer , scheduled for Friday, June 23, 2023.
  • This free virtual event brings together cancer patients, survivors, healthcare professionals, employers and advocates to discuss effective management of treatment, recovery and employment for individuals who have cancer.
  • “Cancer and Careers is an organization that truly understands and demonstrates the importance of supporting individuals with cancer at any stage of their disease while they work or seek employment,” said T.J. Geist, Allsup Principal Advocate.
  • Cancer and Careers’ 2023 national conference will feature several accomplished individuals in the fields of oncology, nutrition, social work and business.

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

Retrieved on: 
Friday, June 9, 2023
PTCL, Hodgkin lymphoma, Abstract, Peripheral T-cell lymphoma, ASH, REDIRECT, Affimer, Bacterial conjugation, Lymphoma, Cancer, Food and Drug Administration, NK, International Conference on Creationism, Poster, Patient, Samsung Medical Center, FDA, IND, Nanakaly Hospital for Hematology & Oncology, Conference, Food, Safety, Pharmaceutical industry, Medical imaging, Book

An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.

Key Points: 
  • An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.
  • Associated with the AFM13-induced cytotoxic activity was an increased functional activation status of AB-101 demonstrated through degranulation and IFN-γ production.
  • Importantly, in a mouse xenograft model, adoptive transfer of AB-101 in combination with AFM13 conferred tumor growth control.
  • The data of AFM13 in combination with the allogeneic, cryopreserved, off-the-shelf, cord blood-derived AB-101 NK cells demonstrate synergistic anti-tumor activity in vivo.

TransCode Therapeutics Announces Closing of $7 Million Public Offering

Retrieved on: 
Friday, June 9, 2023
Therapy, Park Avenue, Cancer, Free File, Research, RNA, Sale, 3rd Floor, Prospectus, Series, Form, Security (finance), IND

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $3.50 per share (or common stock equivalent) and accompanying warrants.

Key Points: 
  • BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $3.50 per share (or common stock equivalent) and accompanying warrants.
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were $7 million.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
San Francisco, Tretinoin, University, European Hematology Association, CALC, University of California, San Francisco, Cancer, Juvenile myelomonocytic leukemia, Patient, Drug combination, Cytarabine, EHA, Calcitriol, Poster, Hospital, FLU, Pharmaceutical industry, JMML

FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own.
  • These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
  • Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
  • Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .

The Oncology Institute (TOI) and Massive Bio Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Retrieved on: 
Friday, June 9, 2023
Partnership, American Oncology Institute, Clinical trial, Cancer, Hope, Intelligence, Research, Patient, Physician, Algorithm, Medicine, AI, Medical device

CERRITOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a non-exclusive partnership with Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients.

Key Points: 
  • CERRITOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a non-exclusive partnership with Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients.
  • This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.
  • Cristina Green, VP of Clinical Research at TOI, commented, “We are excited to announce our partnership with Massive Bio.
  • With our forces joined, more patients will be able to access the most advanced precision medicine available, revolutionizing cancer care.

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Retrieved on: 
Friday, June 9, 2023
STAT3, Peripheral T-cell lymphoma, PD, Cutaneous T-cell lymphoma, Follicular lymphoma, DLBCL, Relapse, ICML, Immunomodulatory imide drug, Lymphoma, Pharmacokinetics, Constipation, TPD, DL2, Abdominal pain, B-cell lymphoma, PBMC, Leukemia, Dizziness, Patient, International Conference on Machine Learning, Plasma, MYD88, Cancer, ABC, Nausea, Toxicity, Infrared spectroscopy correlation table, Therapy, Conference, Safety, Fatigue, Bone marrow, Vaccine, Pharmaceutical industry, Television, Risk management, Medical imaging, IRAK4, Black Majesty, Fever

WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The data were shared in the online abstract book of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland, and reflect a data cut-off date of February 3, 2023. On June 14, a KT-333 poster will be released at ICML and presented on June 16. Kymera will share updated results from both programs in conjunction with the poster release on June 14.

Key Points: 
  • Kymera will share updated results from both programs in conjunction with the poster release on June 14.
  • KT-333 is designed as a potent degrader of STAT3, a transcriptional regulator that has been linked to numerous cancers as well as to inflammatory and autoimmune diseases.
  • As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.
  • As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.